RxDoctor Payments Data

Tony Adar, MD

Procedural Dermatology · Plainview, NYNPI 1588851125

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 30.9% of the total. Reporting peaked in 2023 at $1,160 and has fallen 95.8% since, to $49 in 2025. That places this record below the midpoint for procedural dermatology clinicians in NY, where the typical reported total is $3,601.

$4,120in general payments, 2019–2025

Across 171 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sanofi$478
  • Genentech USA, Inc.$433
  • Novartis$400
  • Almirall LLC$150
  • Regeneron Healthcare Solutions, Inc.$138
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$4,09399%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,120 in reported general payments places this provider in the 50th percentile of 69 procedural dermatology providers in New York.

See all procedural dermatology providers in New York

Medicare billing

Part B allowed, 2024
$971,573
Medicare patients
805
Services billed
6,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa23$506,878
Clobetasol Propionate202$13,483
LevulanAminolevulinic Acid Hcl14$7,239
Cephalexin1,456$6,473
Doxycycline Hyclate229$2,201
Tacrolimus16$1,904
Hydrocortisone72$691
CiclopiroxCiclopirox Olamine11$579
Ketoconazole21$359
Doxycycline Monohydrate25$265
Mupirocin24$175
Fluconazole34$163
Triamcinolone Acetonide16$151
Levocetirizine Dihydrochloride15$115
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim23$67

Paid to pharmacies, not to this prescriber.

Other procedural dermatology in Plainview

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →